Exelixis (EXEL) Free Cash Flow (2010 - 2026)
Exelixis' (EXEL) quarterly Free Cash Flow came in at $250.3 million in Q2 2026, up 20.07% year-on-year from $208.5 million in Q2 2025, and down 24.68% quarter-over-quarter from $332.4 million in Q1 2026.
Exelixis (EXEL) Free Cash Flow (2010 - 2026) Analysis & Trends
Exelixis' Free Cash Flow history runs 17 years deep, the most recent figure standing at $250.3 million for Q2 2026.
- On a quarterly basis, Free Cash Flow rose 20.07% year-over-year to $250.3 million in Q2 2026; TTM through Apr 2026 was $917.7 million, a 11.79% increase from a year earlier, with the FY2026 full-year figure at $875.8 million, up 30.42% from the prior year.
- Free Cash Flow declined to $250.3 million in Q2 2026 per EXEL's latest filing, from $332.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $332.4 million in Q1 2026 and bottomed at -$2.6 million in Q4 2023.
- The 5-year median for Free Cash Flow is $113.0 million (2024), against an average of $142.7 million.
- Across the five-year window, Free Cash Flow plunged 104.01% in 2023 and soared 9315.52% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at $64.0 million in 2022, then plunged by 104.01% to -$2.6 million in 2023, then surged by 10362.91% to $263.1 million in 2024, then climbed by 9.77% to $288.8 million in 2025, then decreased by 13.33% to $250.3 million in 2026.
- Per Business Quant, the three latest EXEL Free Cash Flow figures stand at $250.3 million (Q2 2026), $332.4 million (Q1 2026), and $288.8 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 250.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 250.34 Mn |
| Apr 3, 2026 | 250.34 Mn |
| Jan 2, 2026 | 332.36 Mn |
| Jan 2, 2026 | 332.36 Mn |
| Oct 3, 2025 | 288.84 Mn |
| Oct 3, 2025 | 288.84 Mn |
| Jul 4, 2025 | 46.16 Mn |
| Jul 4, 2025 | 46.16 Mn |
| Apr 4, 2025 | 208.49 Mn |
| Apr 4, 2025 | 208.49 Mn |
| Jan 3, 2025 | 236.29 Mn |
| Jan 3, 2025 | 236.29 Mn |
| Sep 27, 2024 | 263.14 Mn |
| Sep 27, 2024 | 263.14 Mn |
| Jun 28, 2024 | 112.98 Mn |
| Jun 28, 2024 | 112.98 Mn |
| Mar 29, 2024 | 59.13 Mn |
| Mar 29, 2024 | 59.13 Mn |
| Dec 29, 2023 | -2.56 Mn |
| Dec 29, 2023 | -2.56 Mn |